论文部分内容阅读
泰舒(Tace Chlorotrianisene)系非甾体雌激素类药,已收载于英国、美国、苏联等国药典,其活性较已烯雌酚小,属弱雌激素类药物,因此作用较为温和。上海医药工业研究院于1979年完成实验室合成研究工作,其后与苏州第一制药厂共同协怍生产滴丸剂型。泰舒采用化学合成制得,成品经全面质量分析均达到江苏省卫生厅所要求的质量标准,药理试验证实,口服最大耐受量火于10g/kg。泰舒主要治疗妇女更年期综合征、妇女性腺功能不全和男性前列腺疾患,1981年10月开始先后在北京、南京、苏州、常州、无锡等地临床单位进行了373例(包括已烯雌酚对照组114例)临床验证,其中妇女更年
Tace Chlorotrianisene, a non-steroidal estrogen, has been incorporated into the pharmacopoeias of the United Kingdom, the United States, the Soviet Union and other countries. Its activity is less than that of diethylstilbestrol and is a weak estrogen. Shanghai Institute of Pharmaceutical Industry in 1979 to complete the laboratory synthesis research work, and then the first pharmaceutical factory in Suzhou co-production of drip pills. Tai Shu obtained by chemical synthesis, the finished product by a comprehensive quality analysis have reached the quality standards required by the Health Department of Jiangsu Province, pharmacological tests confirmed that the maximum oral fire tolerance in 10g / kg. Tai Shu treatment of menopausal women syndrome, women with gonadal dysfunction and male prostate disease, beginning in October 1981 in Beijing, Nanjing, Suzhou, Changzhou, Wuxi and other clinical units in 373 cases (including the control group of diethylstilbestrol 114 cases) clinical validation, of which women more years